Close Menu
Home › Interpace's ThyraMir Receives Coverage From UnitedHealthcare

Interpace's ThyraMir Receives Coverage From UnitedHealthcare

Apr 18, 2017
|
staff reporter

NEW YORK (GenomeWeb) – Interpace Diagnostics said today that its ThyraMir test for diagnosing thyroid cancer has received coverage from UnitedHealthcare.

With this coverage decision, ThyraMir is now covered for around 250 million patients nationwide, the company said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

What's Popular?

In Molecular Diagnostics

  1. FDA Releases List of Evidence-Based PGx Variants

  2. FIND, WHO Collaborate on Novel Coronavirus MDx Evaluation

  3. Cancer, Pathology Organizations Developing Clinical Guidelines for MMR, MSI Testing

  4. Invitae Q4 2019 Revenues Increase 47 Percent

  5. Novacyt Gets CE Mark for Coronavirus Test

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.